Edesa Biotech Files Q3 2024 10-Q Report
Ticker: EDSA · Form: 10-Q · Filed: Aug 9, 2024 · CIK: 1540159
| Field | Detail |
|---|---|
| Company | Edesa Biotech, Inc. (EDSA) |
| Form Type | 10-Q |
| Filed Date | Aug 9, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceutical, financials
Related Tickers: EDSA
TL;DR
EDSA Q3 10-Q filed. Financials and ops update.
AI Summary
Edesa Biotech, Inc. filed its Q3 2024 10-Q report on August 9, 2024, covering the period ending June 30, 2024. The company, formerly known as Stellar Biotechnologies, Inc., is involved in the pharmaceutical preparations industry. Key financial details and operational updates for the quarter are presented in this filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational status of Edesa Biotech, crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Edesa Biotech faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Edesa Biotech, Inc. (company) — Filer of the 10-Q report
- Stellar Biotechnologies, Inc. (company) — Former name of Edesa Biotech, Inc.
- 20240630 (date) — End of the reporting period
- 20240809 (date) — Filing date of the 10-Q
- PHARMACEUTICAL PREPARATIONS [2834] (industry) — Standard Industrial Classification for Edesa Biotech
FAQ
What is the fiscal year end for Edesa Biotech, Inc.?
Edesa Biotech, Inc.'s fiscal year ends on September 30.
When was Edesa Biotech, Inc. formerly known as?
Edesa Biotech, Inc. was formerly known as Stellar Biotechnologies, Inc., with a date of name change on January 20, 2012.
What is the Standard Industrial Classification code for Edesa Biotech, Inc.?
The Standard Industrial Classification code for Edesa Biotech, Inc. is PHARMACEUTICAL PREPARATIONS [2834].
What is the SEC file number for Edesa Biotech, Inc.?
The SEC file number for Edesa Biotech, Inc. is 001-37619.
What is the business address of Edesa Biotech, Inc.?
The business address of Edesa Biotech, Inc. is 100 SPY COURT, MARKHAM, A6, L3R 5H6.
Filing Stats: 4,523 words · 18 min read · ~15 pages · Grade level 12.4 · Accepted 2024-08-09 16:45:25
Filing Documents
- edsa20240630_10q.htm (10-Q) — 842KB
- ex_706693.htm (EX-31.1) — 12KB
- ex_706694.htm (EX-31.2) — 12KB
- ex_706695.htm (EX-32.1) — 5KB
- ex_706696.htm (EX-32.2) — 5KB
- 0001171843-24-004651.txt ( ) — 4499KB
- edsa-20240630.xsd (EX-101.SCH) — 47KB
- edsa-20240630_def.xml (EX-101.DEF) — 296KB
- edsa-20240630_lab.xml (EX-101.LAB) — 295KB
- edsa-20240630_pre.xml (EX-101.PRE) — 324KB
- edsa-20240630_cal.xml (EX-101.CAL) — 32KB
- edsa20240630_10q_htm.xml (XML) — 647KB
FINANCIAL STATEMENTS
FINANCIAL STATEMENTS Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited) 3 Condensed Interim Consolidated Balance Sheets – June 30, 2024 and September 30, 2023 3 Condensed Interim Consolidated Statements of Operations – Three and Nine Months Ended June 30, 2024 and 2023 4 Condensed Interim Consolidated Statements of Cash Flows – Three and Nine Months Ended June 30, 2024 and 2023 5 Condensed Interim Consolidated Statements of Changes in Shareholders' Equity – Three and Nine Months Ended June 30, 2024 and 2023 6 Notes to Condensed Interim Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.
Controls and Procedures
Controls and Procedures 21 PART II OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 22 Item 1A.
Risk Factors
Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 23 2 PART 1 – FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements Edesa Biotech, Inc. Condensed Interim Consolidated Balance Sheets June 30, 2024 September 30, 2023 Assets: Current assets: Cash and cash equivalents $ 2,040,884 $ 5,361,397 Accounts and other receivable 551,064 626,543 Prepaid expenses and other current assets 454,686 448,912 Total current assets 3,046,634 6,436,852 Non-current assets: Property and equipment, net - 8,702 Long-term deposits 40,661 173,490 Intangible asset, net 2,104,141 2,180,020 Right-of-use assets 36,286 91,373 Total assets $ 5,227,722 $ 8,890,437 Liabilities and shareholders' equity: Current liabilities: Accounts payable and accrued liabilities $ 2,321,810 $ 1,747,150 Short-term right-of-use lease liabilities 38,817 74,714 Total current liabilities 2,360,627 1,821,864 Non-current liabilities: Long-term right-of-use lease liabilities - 19,773 Total liabilities 2,360,627 1,841,637 Commitments (Note 5) Shareholders' equity: Capital shares Authorized unlimited common and preferred shares without par value Issued and outstanding: 3,247,389 common shares (September 30, 2023 - 3,075,473 ) 47,236,024 46,643,151 Additional paid-in capital 13,482,824 13,039,265 Accumulated other comprehensive loss ( 224,791 ) ( 214,648 ) Accumulated deficit ( 57,626,962 ) ( 52,418,968 ) Total shareholders' equity 2,867,095 7,048,800 Total liabilities and shareholders' equity $ 5,227,722 $ 8,890,437 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 3 Edesa Biotech, Inc. Condensed Interim Consolidated Statements of Operations Three Months Ended Nine Months Ended June 30, 2024 June 30, 2023 June 30, 2024 June 30, 2023 Expenses: Research and development $ 897,305 $ 1,025,622 $ 2,778,100 $ 3,841,150 General and administrative $ 1,035,140 $ 1,038,587 $ 3,232,248 3,